查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1698453

肉毒桿菌毒素市場：2025-2030 年預測

Botulinum Toxin Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

肉毒桿菌毒素市場預計將從 2025 年的 85.9 億美元成長到 2030 年的 121.81 億美元，預測期內的複合年成長率為 7.23%。

肉毒桿菌毒素是由革蘭氏陽性厭氧菌肉毒梭菌產生的。肉毒桿菌毒素市場的主要成長動力是人口老化、微創手術的增加、臉部美容手術的激增、非手術選擇數量的增加以及技術創新的進步。其中包括一項關鍵創新：延長 A 型肉毒桿菌毒素的作用時間。另一個主要促進因素是新興市場醫療保健支出的增加。

市場趨勢：

  • 技術進步和新產品開發：技術創新和有希望的研究成果促使製造商開發新產品並力求迅速採用。例如，2024 年 9 月，AEON Biopharma 根據 351(k) 生物相似藥途徑開發了肉毒桿菌複合物。該公司已收到與美國食品藥物管理局(FDA) 就 ABP-450（prabotulinumtoxinA）注射（BOTOX（onabotulinumtoxinA）的生物相似藥）舉行的生物相似藥初步諮詢 (BIA) 會議的正式記錄。
  • 微創手術的需求不斷增加：在技術進步的推動下，肉毒桿菌毒素在微創手術中的應用越來越多。神經調節注射，如肉毒桿菌和真皮填充劑，可以立即產生效果，停機時間最短，已成為保持美麗的重要部分。根據美國整形外科醫師協會的數據，2023 年美國使用 A 型肉毒桿菌毒素（包括 Botox、 Dysport和Xeomin）的手術記錄為 4,715,716 例，與前一年同期比較增加了 6%。
  • 新興經濟體的市場不斷成長：由於可支配收入的增加和整裝儀容意識的增強，中國等國家對肉毒桿菌的需求巨大。
  • 北美處於領先地位：北美仍然是肉毒桿菌毒素的最大消費國，神經調節劑注射被廣泛用於減少皺紋和細紋。軟組織填充劑也越來越受歡迎，可以恢復皮膚的體積和水分。 2023 年，使用神經調節劑注射（Botox、 Dysport、 Xeomin、Jeuveau、Daxify）的微創美容手術達到 9,480,949 例，與前一年同期比較成長 9%。預計這種不斷成長的需求將進一步推動市場擴張。

報告中介紹的關鍵公司包括益普生集團 (Ipsen Group)、Metabiologics、Merz Pharma、Galderma、AbbVie Inc.、Medytox、蘭州生物製品研究所有限責任公司、HUGEL, Inc.、Evolus, Inc.、Revance Therapeutics, Inc. 和 Supernus Pharmaceuticals, Inc.。

本報告的主要優點

  • 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響市場的未來發展。
  • 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業和市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測包括國家在內的細分市場和地區分析
  • 公司概況（策略、產品、財務資訊、主要趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 研究範圍
  • 市場區隔

第3章 商業景氣

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

5. 肉毒桿菌毒素市場（依產品類型）

  • 介紹
  • A型肉毒桿菌毒素
  • B型肉毒桿菌

第6章肉毒桿菌市場（依應用）

  • 介紹
  • 美學應用
  • 治療應用

7. 肉毒桿菌毒素市場（依最終用戶）

  • 介紹
  • 醫院
  • 診所
  • 化妝品中心

8. 肉毒桿菌毒素市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 台灣
    • 其他

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Ipsen Group
  • Metabiologics
  • Merz Pharma
  • Galderma
  • AbbVie Inc.
  • Medytox
  • Lanzhou Institute of Biological Products Co., Ltd.
  • HUGEL, Inc.
  • Evolus, Inc.
  • Revance Therapeutics, Inc.
  • Supernus Pharmaceuticals, Inc.

第11章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615633

The Botulinum Toxins Market, valued at US$12.181 billion in 2030 from US$8.590 billion in 2025, is projected to grow at a CAGR of 7.23% through 2030.

Botulinum toxin is made from Clostridium botulinum, a gram-positive anaerobic bacterium. The major growth drivers for the botulinum toxin market are the aging population, increasing numbers of minimally invasive surgeries, upsurge in facial aesthetics procedures, the rising alternative of non-surgical procedures, and advancement in innovation. This includes increasing the duration of action for Botulinum Toxin Type A, which has been an important innovation. Besides, increased healthcare spending in emerging markets is a major driving factor.

Market Trends:

  • Technological advancements and new product development: Innovations in technology and promising research outcomes have motivated manufacturers to create new products for quicker adoption. For example, in September 2024, AEON Biopharma, Inc. developed a botulinum toxin complex under the 351(k) biosimilar pathway. The company received formal minutes from a Biosimilar Initial Advisory (BIA) meeting with the U.S. Food and Drug Administration (FDA) for ABP-450 (prabotulinumtoxinA) injection, a biosimilar to BOTOX (onabotulinumtoxinA).
  • Rising demand for minimally invasive treatments: Botulinum toxins are increasingly used in minimally invasive procedures, a trend fueled by technological progress. Neuromodulator injections like Botox and dermal fillers have become integral to aesthetic maintenance, offering immediate results with minimal downtime. In 2023, the U.S. recorded 4,715,716 procedures using botulinum toxin type A (including Botox, Dysport, and Xeomin), marking a 6% increase from the previous year, according to the American Society of Plastic Surgeons.
  • Growing market in emerging economies: Countries like China are witnessing significant demand for botulinum toxins, driven by rising disposable incomes and heightened awareness of personal appearance. This has expanded the market, as more individuals are willing to invest in cosmetic treatments.
  • North America's leading role: North America remains a major consumer of botulinum toxins, with neuromodulator injections widely used to reduce wrinkles and fine lines. Soft tissue fillers are also increasingly popular for restoring volume and hydration to the skin. In 2023, cosmetic minimally invasive procedures using neuromodulator injections (Botox, Dysport, Xeomin, Jeuveau, Daxxify) reached 9,480,949, a 9% increase from the previous year. This growing demand is expected to further drive market expansion.

Some of the major players covered in this report include Ipsen Group, Metabiologics, Merz Pharma, Galderma, AbbVie Inc., Medytox, Lanzhou Institute of Biological Products Co., Ltd., HUGEL, Inc., Evolus, Inc., Revance Therapeutics, Inc., and Supernus Pharmaceuticals, Inc., among others:

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Botulinum Toxins Market is analyzed into the following segments:

By Product Type

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

By Application

  • Aesthetic Applications
  • Therapeutic Applications

By End User

  • Hospitals
  • Clinics
  • Cosmetic Centers

By Region

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BOTULINUM TOXINS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Botulinum Toxin Type A
  • 5.3. Botulinum Toxin Type B

6. BOTULINUM TOXINS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Aesthetic Applications
  • 6.3. Therapeutic Applications

7. BOTULINUM TOXINS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Cosmetic Centers

8. BOTULINUM TOXINS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Application
    • 8.3.3. By End User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Application
    • 8.4.3. By End User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Application
    • 8.5.3. By End User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Application
    • 8.6.3. By End User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Ipsen Group
  • 10.2. Metabiologics
  • 10.3. Merz Pharma
  • 10.4. Galderma
  • 10.5. AbbVie Inc.
  • 10.6. Medytox
  • 10.7. Lanzhou Institute of Biological Products Co., Ltd.
  • 10.8. HUGEL, Inc.
  • 10.9. Evolus, Inc.
  • 10.10. Revance Therapeutics, Inc.
  • 10.11. Supernus Pharmaceuticals, Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations